We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
GENEART AG will Become Part of the US-Based Biotechnology Company Life Technologies Corp
News

GENEART AG will Become Part of the US-Based Biotechnology Company Life Technologies Corp

GENEART AG will Become Part of the US-Based Biotechnology Company Life Technologies Corp
News

GENEART AG will Become Part of the US-Based Biotechnology Company Life Technologies Corp

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "GENEART AG will Become Part of the US-Based Biotechnology Company Life Technologies Corp"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

The founders of GENEART AG Prof. Dr. Ralf Wagner, Prof. Dr. Hans Wolf, Dr. Marcus Graf, and individual members of the management as well as the venture capital companies EquiNet EarlyStage Capital and S-REFIT AG, have signed contracts with Applied Biosystems Deutschland GmbH for selling their GENEART shares.

Applied Biosystems Deutschland GmbH thus holds about 58 % of GENEART AG shares and is planning a voluntary public tender offer for the remaining GENEART AG shares. Applied Biosystems Deutschland GmbH is the German subsidiary of Life Technologies Corporation, a California/US biotechnology company with 2009 revenues of 3.3B U.S. dollar and about 9,000 employees. Furthermore, a cooperation agreement between GENEART AG and Life Technologies has been concluded.
Advertisement